BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 26343386)

  • 21. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.
    Niu HT; Zhou QM; Wang F; Shao Q; Guan YX; Wen XZ; Chen LZ; Feng QS; Li W; Zeng YX; Zhang XS
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):646-53. PubMed ID: 23751074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
    Nikolaev SI; Rimoldi D; Iseli C; Valsesia A; Robyr D; Gehrig C; Harshman K; Guipponi M; Bukach O; Zoete V; Michielin O; Muehlethaler K; Speiser D; Beckmann JS; Xenarios I; Halazonetis TD; Jongeneel CV; Stevenson BJ; Antonarakis SE
    Nat Genet; 2011 Dec; 44(2):133-9. PubMed ID: 22197931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
    Mar VJ; Wong SQ; Logan A; Nguyen T; Cebon J; Kelly JW; Wolfe R; Dobrovic A; McLean C; McArthur GA
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1117-25. PubMed ID: 25043693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
    Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
    Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
    Krauthammer M; Kong Y; Bacchiocchi A; Evans P; Pornputtapong N; Wu C; McCusker JP; Ma S; Cheng E; Straub R; Serin M; Bosenberg M; Ariyan S; Narayan D; Sznol M; Kluger HM; Mane S; Schlessinger J; Lifton RP; Halaban R
    Nat Genet; 2015 Sep; 47(9):996-1002. PubMed ID: 26214590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.
    Dutton-Regester K; Kakavand H; Aoude LG; Stark MS; Gartside MG; Johansson P; O'Connor L; Lanagan C; Tembe V; Pupo GM; Haydu LE; Schmidt CW; Mann GJ; Thompson JF; Scolyer RA; Hayward NK
    Pigment Cell Melanoma Res; 2013 Nov; 26(6):852-60. PubMed ID: 23890154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
    Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
    Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Genetic Evolution of Melanoma from Precursor Lesions.
    Shain AH; Yeh I; Kovalyshyn I; Sriharan A; Talevich E; Gagnon A; Dummer R; North J; Pincus L; Ruben B; Rickaby W; D'Arrigo C; Robson A; Bastian BC
    N Engl J Med; 2015 Nov; 373(20):1926-36. PubMed ID: 26559571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NF1 Mutations Prevalent but Not Clinically Relevant.
    Cancer Discov; 2015 Oct; 5(10):OF1. PubMed ID: 26283687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma.
    Sun W; Liu K; Zhou H; Zhao F; Dong Y; Xu Y; Kong Y; Wang M; Cheng X; Chen Y
    Med Oncol; 2023 Oct; 40(11):330. PubMed ID: 37831226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
    Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
    Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.